Salmex registered in another Central American country

Salmex received marketing authorisation on another foreign market – in Honduras – it will be marketed under the name Ventiflu Discus. The marketing authorisation process was intermediated by the Company’s business partner under a commercial agreement. Honduras is another market in Central America, after Guatemala and El Salvador, where the Company has registered its product.Read more »

Maciej Wieczorek is a member of the jury of the Polish President’s Economic Award

President of the Management Board of Celon Pharma S.A. was appointed a member of the jury for the 14th edition of the Polish President’s Economic Award. Maciej Wieczorek joined the interdisciplinary group of experts representing business, science, media, non-governmental organisations and capital market institutions, who will nominate companies for the Polish President’s Economic Award. ThisRead more »

Celon Pharma S.A. at the 2018 BIO International Convention

Between 4 and 7 June this year, representatives of our Company are taking part in the largest global Life Sciences networking meeting. Our participation at this event is one of the elements of our implementing our strategy to increase Celon Pharma’s international presence and our planned global commercialisation of the Company’s innovative portfolio. Bogdan Manowski, DirectorRead more »

Finalised DCP registration procedure for Salmex at the German market

In the German market, Salmex will be available under the trade name Salflutin. After completing the DCP registration procedure, the German drug registration authority will verify the national version of the information materials (including the leaflet, the medicine package) and will issue a final decision on marketing authorisation within the time limits set by theRead more »

Celon Pharma S.A. at BioForum 2018

Maciej Wieczorek, President of Celon Pharma S.A., will take part in this year’s Bioforum 2018, where he will hold a presentation on the novel approach to drug discovery and development process. Bioforum is one of the largest meetings of the biotechnology industry in Poland. This year it will be organised for the 17th time andRead more »

Celon Pharma S.A. significantly increases its net profit in the first quarter of 2018 and improves production and sales efficiency while on its way to conquer other European markets

Over 28 million net revenues from sales of products, goods and materials; PLN 7.5 million of net profit – as compared to approx. PLN 5 million in the first quarter of 2017; A 7% quantitative growth of products sold and strengthening the leading position of most drugs from the portfolio in their respective therapeutic groups.Read more »

Celon Pharma is a business partner of StarShip as part of EIT Health

Celon Pharma representatives are taking part in the StarShip conference which takes place between 7 and 11 of May in Łódz. The purpose of the meeting is to inspire young people from all over Europe to take business and scientific initiatives in the field of Research and Development and in innovative branches of the economy.Read more »